Comparison

Danusertib (PHA-739358) European Partner

Manufacturer Selleckchem
Category
Type Inhibitors
Specific against other
Amount 50 mg
Item no. S1107-50
Targets RET, BCR
CASRN 827318-97-8
eClass 6.1 30220300
eClass 9.0 32160605
Available
Administration
Intraperitoneally
Animal Models
Female SCID mice
Cell lines
CD34+ cells
Chemical Name
(R)-N-(5-(2-methoxy-2-phenylacetyl)-1, 4, 5, 6-tetrahydropyrrolo[3, 4-c]pyrazol-3-yl)-4-(4-methylpiperazin-1-yl)benzamide
Clinical Trials
Danusertib is currently in a Phase II clinical trial in the treatment of leukemia.
Concentrations
5 uM
Description
Danusertib (PHA-739358) is an Aurora inhibitor for Aurora A/B/C, Bcr-Abl, c-RET and FGFR with IC50 of 13 nM/79 nM/61 nM, 25 nM, 31 nM and 47 nM, respectively.
Dosages
15 mg/kg
Formulation
In DMSO
IC50
13 nM/79 nM/61 nM, 13 nM/79 nM/61 nM, 13 nM/79 nM/61 nM, 13 nM/79 nM/61 nM, 13 nM/79 nM/61 nM, 13 nM/79 nM/61 nM
In vitro
Danusertib inhibits the activities of other kinases such as FGFR1, Abl, Ret and Trka, with IC50 of 47 nM, 25 nM, 31 nM and 31 nM, respectively. In a cell assay, after treatment of wild-type and p53-deficient MEFs with Danusertib, the wild-type cells undergo an arrest in mitosis (4N) that is maintained for up to 48 h. The p53-deficient cells on the other hand do not arrest at the 4N DNA stage, but continues with additional rounds of DNA synthesis to become >8N. Treatment with Danusertib results in an increase in p53 protein levels and an associated increase in p21 protein, which is known to be transcriptionally regulated by p53. [1] Increasing concentrations of Danusertib produces a dose-dependent reduction of cell growth after 48 hours in BCR-ABL–positive (K562, BV173) and BCR-ABL–negative (HL60) cells. [3]
In vivo
Administration of 25 mg/kg Danusertib (b.d. i.v.) to HL-60 xenograft rats results in 75% inhibition of tumor growth with complete regression in one animal. Danusertib results in biomarker modulation accompanied by inhibition of tumor growth. This is compatible with an expected mechanism of action of aurora kinase inhibition. [1] Danusertib significantly inhibits proliferation of K562 cells and virtually suppressed tumor growth during the 10-day treatment period. [3]
Incubation Time
5 days
Kinase Assay
Biochemical kinase Assays, The Km values for ATP and the specific substrate are initially determined, and each assay is then run at optimized ATP (2Km) and substrate (5Km) concentrations. This setting enabled direct comparison of IC50 values of Danusertib across the applied kinase selectivity screening panel for the evaluation of the selectivity profile.
Method
For short-term expansion assays, 1 x 103 CD34+ cells are plated in triplicates in 96-well plates containing 100 uL of serum-free medium per well supplemented with human stem-cell factor (100 ng/mL), human Flt-3 Ligand (100 ng/mL), human thrombopoietin (50 ng/mL), human interleukin-3 and -6 (IL-3 and IL-6, respectively, both 20 ng/mL), and granulocyte colony-stimulating factor (20 ng/mL) along with Danusertib at the indicated concentrations. After 5 days, an additional 100 uL of cytokine and Danusertib containing medium are added. Cell numbers within each individual well are estimated on days 3, 6, and 9 or on days 3, 6, and 12 for healthy donor samples.
Molecular Weight (MW)
474, 55
Picture ChemicalStructure Description
Danusertib (PHA-739358) Chemical Structure
Picture Description 1
, , Dr. Yong-Weon Yi from Georgetown University Medical Center, Danusertib (PHA-739358)purchased from Selleck, For MTT assays, cells (2, 000 ca. 5, 000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of PHA-739358 by adding 20 l of 5 mg/ml 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) solution per 100 l of growth medium. After incubating for 3-4 h at 37C, the media were removed and 150 l/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.
Picture Description 2
, , Dr. Zhang, of Tianjin Medical University, Danusertib (PHA-739358)purchased from Selleck, Western blot analysis of Histone and Aurora kinase. 0-10M PHA739358 was added.
Solubility (25C)
DMSO 95 mg/mL, Water <1 mg/mL, Ethanol <1 mg/mL
Storage
2 years -20CPowder, 2 weeks4Cin DMSO, 2 months-80Cin DMSO

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 50 mg
Available: In stock
available

Delivery expected until 5/16/2024 

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close